Overview

A Phase III Trial To Evaluate The Efficacy And Safety Of MC2-01 Cream Compared To CAL/BDP Gel and Vehicle In Plaque Psoriasis Subjects

Status:
NOT_YET_RECRUITING

Trial end date:
2026-12-17

Target enrollment:

Participant gender:

Summary

This is a multi-center, randomized, investigator-blinded, calcipotriol and betamethasone dipropionate gel and vehicle-controlled phase 3 clinical study to evaluate the efficacy and safety of MC2-01 cream in the treatment of Chinese plaque psoriasis to assess the efficacy and safety of MC2-01 cream in Chinese subjects aged 18 years with plaque psoriasis. This study includes a screening period, a treatment period, and a safety follow-up period.

Phase:

PHASE3

Details

Lead Sponsor:

Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.

Collaborator:

MC2 Therapeutics